How many insider trades does FilingIQ track for PHVS?

FilingIQ tracks 53 Form 4 insider transactions for PHVS (Pharvaris N.V.), covering filings from Apr 1, 2026 onwards. 53 of those were filed in the last 90 days.

Are PHVS insiders net buyers or net sellers?

Across the full Form 4 history for PHVS, 0 transactions (0%) were open-market purchases and 24 (45%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PHVS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is PHVS in?

Pharvaris N.V. (PHVS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.86B.

PHVS insider trading

NasdaqGS Healthcare

Pharvaris N.V. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 45%

Market cap

$1.86B

About Pharvaris N.V.

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Company website: pharvaris.com

PHVS insider activity at a glance

FilingIQ has scored 53 insider transactions for PHVS since Apr 1, 2026. The most recent filing in our index is dated May 12, 2026.

Across the full history, 0 open-market purchases and 24 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on PHVS insider trades is 60.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live PHVS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for PHVS?: FilingIQ tracks 53 Form 4 insider transactions for PHVS (Pharvaris N.V.), covering filings from Apr 1, 2026 onwards. 53 of those were filed in the last 90 days.
Are PHVS insiders net buyers or net sellers?: Across the full Form 4 history for PHVS, 0 transactions (0%) were open-market purchases and 24 (45%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does PHVS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is PHVS in?: Pharvaris N.V. (PHVS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.86B.

Methodology & sources

Every PHVS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.